{"id":"W2402233591","doi":"10.1200/jco.2016.67.0182","title":"Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Cancer Care Ontario; American Society of Clinical Oncology","keywords":"Medicine; Trastuzumab; Oncology; Docetaxel; Internal medicine; Guideline; Breast cancer; Taxane; Regimen; Carboplatin; Context (archaeology); Population; Anthracycline; Cancer; Gynecology; Chemotherapy; Pathology; Cisplatin","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01770985,0.0009228201,0.001632306,0.003148525,0.001503073,0.00252113,0.004427014,0.003954528,0.002285013],"category_scores_gemma":[0.03604361,0.000659137,0.002924455,0.003195436,0.001222235,0.001649392,0.001788584,0.005460862,0.001306143],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01405698,"about_ca_system_score_gemma":0.06578337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1270037,"about_ca_topic_score_gemma":0.2867988,"domain_scores_codex":[0.9861045,0.004855051,0.002858968,0.00045999,0.004948873,0.0007725346],"domain_scores_gemma":[0.9663976,0.005138591,0.003280687,0.0004863044,0.02282572,0.001871022],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001230657,0.0003150183,0.005479197,0.007851401,0.0002216841,0.0005836278,0.001249075,0.002850958,0.001649637,0.006136205,0.6763642,0.297176],"study_design_scores_gemma":[0.0006243247,0.0002104197,0.01871628,0.04075069,0.000813427,0.0008064521,0.0008719394,0.003379206,0.001095471,0.005981416,0.9265612,0.0001891519],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.02435466,0.1878269,0.05616241,0.5018213,0.01283925,0.02821876,0.0140467,0.0009500267,0.17378],"genre_scores_gemma":[0.1208191,0.225555,0.4548703,0.1165938,0.004153579,0.01648621,0.02774249,0.0003503497,0.03342917],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.985943,"threshold_uncertainty_score":0.2525288,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1880175702403382,"score_gpt":0.5514264082407141,"score_spread":0.3634088380003759,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}